News | October 23, 2025
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Globally, BRUKINSA is approved in more than 70 countries
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Subscribe To Our Newsletter & Stay Updated
